Contract Research Organization for Nonclinical Testing
Who We Are
SEKISUI XenoTech is a specialty global Contract Research Organization (CRO) specializing in ADME/DMPK/DDI testing of potential drug candidates.
Utilized by top pharma companies, biotechs, and numerous other organizations, we provide the finest tools and resources to advance the development of effective, safe drugs. By helping our clients understand as much as possible about their drugs, they have the best chance of getting to clinical trials, and ultimately to the market where patients may benefit. As a premier provider of in vitro drug metabolism and drug-drug interaction studies to pharmaceutical companies worldwide, we have unparalleled experience in evaluating drug candidates as substrates, inhibitors, and inducers of drug-metabolizing enzymes and drug transporters.
In 1994, Dr. Andrew Parkinson was working in a lab at the University of Kansas Medical Center studying xenobiotics and recognized the growing need for drug developers to have an expert partner they could trust to explore the complexity of potential pathways of a drug through the body—much more work than one small university lab could handle. Thus, XenoTech was started by Dr. Parkinson and a small group of ambitious scientists eager to apply their expertise to the development of safe, effective therapies for the patients that need them. In 2008, XenoTech joined the SEKISUI family and gained a sister lab across the world in Tokai, Japan, specializing in in vivo ADME studies…
Our products and contracted services are used to help drug developers all over the world find out more about their compounds. Explore the many questions in nonclinical drug development we help researchers and industry professionals to answer every day.